An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Clinical trial NCT06075537 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT06075537
Sponsor: Denali Therapeutics Inc.
Status: ENROLLING_BY_INVITATION
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Mucopolysaccharidosis II

Start date: 2023-09-20
Primary completion: 2027-06-01
Enrollment: 99

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.